Evaluating the effects of acromegaly on hand and foot dimensions and movement

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the impact of acromegaly on the morphology and functionality of hands and feet in patients. Utilizing a 3D scanning system, the study will measure the geometrical and volumetric characteristics of the extremities in both newly diagnosed patients and those with varying disease statuses. Additionally, gait analysis will be performed to evaluate posture and balance control during walking. The study seeks to provide insights into the physical alterations caused by acromegaly and the effects of medical or surgical therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* De novo patients with acromegaly (group # 1), diagnosed according to Endocrine Society guidelines,
* Age equal to18 years or older
* Acromegalic patients with different disease status (group #2)
* Age equal to18 years or older

Exclusion Criteria:

* Cardiorespiratory, neurological or musculoskeletal disorder
* Previous orthopaedic surgery
* Previous lower limbs traumatic injuries

Where it's running

• Istituto Auxologico Italiano IRCCS San Luca
  Milan, Italy Recruiting

Study contacts

• Principal investigator: Giovanni Vitale — Istituto Auxologico Italiano IRCCS
• Study coordinator: Sara Farina, Doctor
• Email: sara.farina@unimi.it
• Phone: +393386822298

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NTQ6179 tablets first-in-human test in healthy adults

  This phase 1 study tests a single oral dose of NTQ6179 vs placebo in healthy adults to see if it is safe and how the body processes the drug.

  Recruiting Phase 1 Nanjing Chia-tai Tianqing Pharmaceutical · Beijing · NCT07909837

• Test MAR002 for acromegaly in adults on or off medical therapy

  This study tests whether subcutaneous MAR002 is safe and tolerable in adults with acromegaly, compared with a placebo, over 10 weeks.

  Recruiting at 3 sites Phase 2 Marea Therapeutics · Phoenix, Arizona and 2 other locations · NCT07641179

• Octreotide SC Depot in Acromegaly: Real-World Safety and Effectiveness

  This study follows people with acromegaly who are using octreotide subcutaneous depot to see how it works and how safe it is over up to two years in everyday clinical practice.

  Recruiting at 4 sites Camurus AB · Aachen and 6 other locations · NCT07583563

• MAR002 in healthy men

  This trial tests whether a subcutaneous injection of MAR002 is safe and tolerable in healthy men aged 18 to 40.

  Recruiting Phase 1 Marea Therapeutics · Tempe, Arizona · NCT07195175

• Pasireotide LAR and bone health in adults with acromegaly

  This study will test whether switching adults with uncontrolled acromegaly to pasireotide LAR changes bone turnover and the risk of vertebral fractures.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Rome, RM · NCT07179926

• Assessing Debio 4126 for treating acromegaly in patients on somatostatin analogs

  This study is testing if a new treatment called Debio 4126 can help people with acromegaly who are already on somatostatin analogs keep their IGF-1 levels in check better than a placebo.

  Recruiting at 72 sites Phase 3 Debiopharm International SA · Los Angeles, California and 73 other locations · NCT06930625

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.